Replies to post #72787 on Biotech Values

[corpstrat]

<<the lack of 5% holders other than Roche makes such an outcome nonsensical, and hence the IB provision is highly unlikely to come into play>>

Thanks. Without drawing a tree, I'm never going to get the logic right, but seem to have leapt to the right conclusion that IBs are not going to rescue the value.

Where is the DNA survey coming out in predicting the outcome?